Literature DB >> 28392590

Health care's ills: A Catholic diagnosis.

Angus Sibley1.   

Abstract

Catholic teaching is emphatic on the need to "guarantee adequate [health] care to all," as Pope Benedict XVI has stated. America has been slower than other advanced countries in progressing towards this goal. Reasons for this delay can be found in certain attitudes that have long been present in American culture, and have been reinforced by the wave of libertarianism (free-market ideology) that swept the world in the late twentieth century. Catholic theology and social/economic teaching can help us understand the flaws in these attitudes, which involve fundamental philosophical and theological principles, but which are far from academic, since they have serious and very practical consequences. In the light of Catholic teaching, we can look towards a sounder understanding of healthcare needs and effective ways of meeting them. Lay Summary: This article argues that access to healthcare, at least up to the level of basic necessity, falls under the heading of distributive justice. It is a human right owed by the community to each of its citizens. And since rights entail obligations, this right entails an obligation upon each citizen to contribute, as circumstances permit, to the costs, which need to be shared equitably; they cannot be met simply by each individual providing solely for oneself. Also discussed are the problems of excessive costs in healthcare administration and in pharmacological research, as well as harmful tendencies in private-sector firms to over-reward top management and to target maximum (rather than adequate) profits.

Entities:  

Keywords:  Catholic economic teaching; Catholic social teaching; Healthcare reform; Solidarity; Universal health coverage

Year:  2016        PMID: 28392590      PMCID: PMC5375597          DOI: 10.1080/00243639.2016.1249264

Source DB:  PubMed          Journal:  Linacre Q        ISSN: 0024-3639


  9 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

Review 2.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

3.  Should Canada allow direct-to-consumer advertising of prescription drugs?: no.

Authors:  Barbara Mintzes
Journal:  Can Fam Physician       Date:  2009-02       Impact factor: 3.275

4.  How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.

Authors:  Tito Fojo; Christine Grady
Journal:  J Natl Cancer Inst       Date:  2009-06-29       Impact factor: 13.506

5.  Pharmaceutical research and development: what do we get for all that money?

Authors:  Donald W Light; Joel R Lexchin
Journal:  BMJ       Date:  2012-08-07

6.  United Kingdom (Scotland): Health system review.

Authors:  David Steel; Jonathan Cylus
Journal:  Health Syst Transit       Date:  2012

7.  The hyperthyroid economy.

Authors:  D E Sibley
Journal:  J R Soc Med       Date:  1995-06       Impact factor: 5.344

8.  Pharmaceutical regulation in Europe and its impact on corporate R&D.

Authors:  Stephan Eger; Jörg C Mahlich
Journal:  Health Econ Rev       Date:  2014-10-03

9.  The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States.

Authors:  Marc-André Gagnon; Joel Lexchin
Journal:  PLoS Med       Date:  2008-01-03       Impact factor: 11.069

  9 in total
  1 in total

1.  Religious Perspectives on Precision Medicine in Singapore.

Authors:  Hui Jin Toh; Angela Ballantyne; Serene Ai Kiang Ong; Chitra Sankaran; Hung Yong Tay; Malminderjit Singh; Raza Zaidi; Roland Chia; Sarabjeet Singh; Swami Samachittananda; You Guang Shi; Zhixia Tan; Tamra Lysaght
Journal:  Asian Bioeth Rev       Date:  2021-09-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.